NUFLOR GOLD vs Draxxin®

 

Comparison of NUFLOR GOLD (florfenicol) Antibiotic and Draxxin® (tulathromycin) for Treatment of BRD in Feedyard Cattle with a 7-Day Post Treatment Interval

Abstract. In November 2008, a clinical study was initiated to compare the effects of NUFLOR GOLD to Draxxin as a first line therapy for bovine respiratory disease (BRD). In this 60-day study, 927 high risk, cross-bred beef heifers with an average in-weight of 542 pounds were candidates for the study. As animals qualified for the study (n=244), they were randomly treated with either NUFLOR GOLD or Draxxin, and both groups used a 7-day post treatment interval (PTI).

The overall morbidity for the candidate pool was 26%, and mortality was 2.6%. There was no difference in first (p=0.42) or second (p=0.12) treatment success rates for NUFLOR GOLD and Draxxin. There was no difference in the BRD case fatality rate between NUFLOR GOLD and Draxxin (p=0.57). Additionally the weight gain (p=0.80) and ADG (p=0.81) for this 60-day study was not different between NUFLOR GOLD and Draxxin. These data indicate that NUFLOR GOLD exhibited equivalent performance to Draxxin as a first line BRD therapy with a 7-day PTI.

Study Animals

  • 927 beef heifers
  • Average in-weight 542 lbs

Study Design

  • Timing: Winter 2008-2009
  • Randomized, blinded trial
  • Natural BRD clinical trial
  • Metaphylaxis: Excede®
  • Trial duration: 60 days
  • Location: Texas feedyard

Enrollment Criteria

  • Respiratory or depression score greater than 2 (2 of 4)
  • Rectal temperature ≥ 104ºF

Treatments and Dosing

Initial Therapy:

  • NUFLOR GOLD 40 mg/kg [6 mL/cwt], SQ, once, 7-day PTI
  • Draxxin 2.5 mg/kg [1.1 mL/cwt], SQ, once, 7-day PTI

Second treatment: Baytril®

Outcomes

  • Morbidity and mortality
  • Body weight gains
  • Feeding performance

Results. After metaphylaxis with Excede and a 3-day treatment moratorium, there were 224 eligible candidates enrolled in the study. The first treatment success was not different (p=0.42) between cattle receiving NUFLOR GOLD (66) and those receiving Draxxin (70). Second treatment success was not different (p=0.12) between groups. (See Graph 1.) However, all cattle received the same antibiotic therapy (Baytril) for the second respiratory treatment. Despite this tendency, BRD mortality did not differ (p=0.57) between NUFLOR GOLD (13) and Draxxin (11) treatment groups. The case fatality rates of 10.5% and 8.3% for NUFLOR GOLD and Draxxin, respectively (see Table 1), were not significantly different (p=0.57).

Initial weight on test (p=0.34), collected at the time of cattle enrollment on the study, and final weights (p=0.80) did not differ among treatments. (See Graph 2.) The total weight gains of 97 pounds for NUFLOR GOLD and 96 pounds for Draxxin were not different (p=0.80). In addition the ADG during the 60-day study period for NUFLOR GOLD (1.67 lbs/day) and Draxxin (1.60 lbs/day) did not differ (p=0.81). (See Table 2.)

Increased respiratory treatments from either group were associated with lower weight gains during this 60-day treatment study. Animals treated one, two, or three times for BRD (regardless of group) gained 114.6 pounds (1.91 lbs/day), 60.9 lbs (1.01 lbs/day) and 33.4 lbs (0.56 lbs/day), respectively.

Graph 1. Treatment Success for Cattle Treated with NUFLOR GOLD or Draxxin

Graph 1. Treatment Success for Cattle Treated with NUFLOR GOLD or Draxxin
Table 1. Mortality Summary of Cattle Treated with NUFLOR GOLD
or Draxxin as First Line Therapy for BRD with a 7-Day PTI
Treatment BRD Deads BRD Case Fatality
NUFLOR GOLD 13 10.5%
Draxxin 11 8.3%
p value 0.57 0.57

Graph 2. Average Body Weights of Cattle with BRD and Treated with NUFLOR GOLD or Draxxin

Graph 2. Average Body Weights of Cattle with BRD and Treated with NUFLOR GOLD or Draxxin
Table 2. Performance Summary of Cattle Treated with NUFLOR GOLD
or Draxxin as First Line Therapy for BRD with a 7-day PTI
Treatment Total Weight Gain (lbs) ADG (lbs/day)
NUFLOR GOLD 97 1.62
Draxxin 96 1.60
p value 0.80 0.81

Conclusions. This study showed a typical incidence of morbidity and mortality often noted for high risk cattle entering feedyards in the Texas panhandle. The morbidity for the candidate pool was 26% (range 11% to 41%), and the death loss was 2.6% (range 1.1% to 4.4%). After a candidate was qualified and treated with NUFLOR GOLD or Draxxin, a 7-day PTI was observed. A PTI is a commonly used tool that allows for more recovery time for cattle and can help reduce labor and medicine costs. Following the 7-day PTI, the first treatment success rates for NUFLOR GOLD and Draxxin did not differ. There were no significant differences in total body weight gains or average daily gains of cattle in this study. Overall this study shows that NUFLOR GOLD performed similarly to Draxxin as first line therapy for BRD following a 7-day PTI. NUFLOR GOLD is an excellent choice for the first line treatment of bovine respiratory disease.

 

The Importance of
Mycoplasma bovis

People who chose Nuflor Mycoplasma bovis is now being recognized for its dual role in BRD: causing infection and accelerating infection by other bacteria.
Learn More

Causes and Signs of BRD